DNA samples from 231 unselected patients with cataracts were studied to determine the frequency of the DM mutation in cataract patients. A previous epidemiological study established a high prevalence of DM in the population of Guipuzcoa (Basque Country, Spain), 26-5 cases/100 000. We have found two carriers (0'9%) of the DM mutation in patients who are not related to any previously known DM family. The screening of the DM mutation in cataract patients should be restricted to young patients or people with multicoloured and iridescent opacities, in which the risk of carrying the DM premutation could be higher. Our results suggest that subjects with 38 to 80 repeats could constitute the genetic reservoir of the DM mutation.
In the absence of any evident clinical features, identification of typical subcapsular opacities in subjects at risk of myotonic dystrophy (DM) was used as an indicator of a minimally affected gene carrier before the characterisation of the DM mutation. The identification of a specific mutation involving an unstable CTG repeat sequence in DM patients'-3 has provided an accurate molecular test for the disorder, and has allowed the detection of minimally affected subjects with a premutation (50 to 100 CTG repeats).' DM premutation carriers with cataracts and no family history of DM could constitute the genetic reservoir of the DM mutation in the population. In a recent and extensive epidemiological study, in which we have tested nearly all the members of the families with the disease, we Two DM premutation carriers were found. One of them was a 74 year old man with diabetes and arterial hypertension, who had an expansion of 80 CTG repeats, and the other was a 47 year old woman with an expansion of 55 CTG repeats. Both of them came from the Bajo-Deba area of Guipuizcoa where the prevalence of the disease is the highest (30.9/ 100 000).5 Discussion Until now, only two studies have analysed the risk to cataract patients of being DM carriers." 12 Harley et all" found no DM carriers among 101 cataract patients." Kidd et all'2 found six patients with the DM mutation out of 1 3 patients studied (17 were analysed retrospectively). However, their inclusion criteria were not as strict as ours, since three had signs, symptoms, and even an evident familial history ofDM, whereas in our study these patients were excluded. Considering only the other three patients, the prevalence of DM among cataract patients found by Kidd et all2 is higher than ours. This could be because of the age difference in both series; the patients younger than 60 (inclusion criteria in the study of Kidd et all2 constitute only 11% of our sample. We have observed that 0 9% ofour cataract patients carry the DM premutation. The percentage obtained is very low to recommend genetic screening for the DM mutation in all the cataract patients. However, we must consider the importance of the detection of DM premutation carriers, owing to the anticipation phenomenon. These subjects are at risk of having children with typical DM and grandchildren with congenital DM, especially when the DM premutation is transmitted by a male. 13 The detection of DM premutation carriers could help to prevent the occurrence of congenital cases in families without a clinical history of typical DM. Screening for the DM mutation in cataract patients should be restricted to young patients or subjects with multicoloured and iridescent opacities, in whom the risk of carrying the DM premutation could be higher. It is interesting to note that in our study, a frequency of the DM mutation of 1/26 in the age group less than 60 years was found, whereas in those over 60 years, the proportion was only 1/203.
It has been postulated that "trinucleotide diseases" like myotonic dystrophy could be time bombs within the human genome.'4 The strong tendency towards expansion of repeats, shown by Rubinsztein et all5 in Huntington disease,'5 would lead to a steady increase over time in the frequency of alleles in the premutation range coming from alleles at the highest end of the normal range. However, in our cataract patients, we have not found subjects in the 33 to 50 repeat range, which could be ready to pass the threshold in few generations. Moreover, we have not found intergenerational variation in the transmission of normal CTG repeats (5 to 37) in 346 parent-child pairs, of which 62 were transmissions of alleles in the 19 to 33 repeat range.'6 Unfortunately we were not able to study the parents (dead) who transmitted the DM mutation to our two cataract patients. The 47 year old woman with 55 repeats had no first degree relatives and the offspring of the other patient declined to participate in the study. Even if the patients had not had a direct relationship with any known DM family, we suspect they could belong to asymptomatic unknown collateral branches of symptomatic DM families which were not included in our epidemiological study.5 In the first case, the patient was from a small village with a high prevalence of DM and the other patient shared the same rare family name as a known DM family from a neighbouring province.
The genetic reservoir of the disease could be the generally mildly affected patients (with cataracts as the only sign of the disease) in the 38 to 80 (CTG). range, derived from collateral branches of DM pedigrees. Some premutated alleles between 38 and 80 repeats can expand from 120 and up to 1000 repeats in some cases especially in male transmissions,'7-19 while in other cases, the premutated alleles are transmitted silently over generations."' The alleles which expand would replace the losses owing to the reduction in fitness and marriage produced by the disease.20 For a better understanding of the dynamics of the DM mutation in this range, the next step should be the study of 
